Alyea Therapeutics, a biotech firm focused on non-opioid pain treatments, will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. CEO Amol Soin will hold investor meetings and present the company's pipeline, including low-dose naltrexone for Complex Regional Pain Syndrome and a topical pain-relief patch. This event offers Alyea a platform to attract investment and highlight its strategy to develop clinically meaningful therapies addressing unmet needs in chronic pain management.
Dave & Buster's Entertainment reported a Q2 2026 earnings per share (EPS) of -$0.27, missing analyst expectations of $0.18, and posted an adjusted net loss of $9.50 million, reversing last year's profits. Revenue fell 2.4% year-over-year to $544.10 m...
Hub Group's stock is falling due to an expected operating loss in the first half of 2026 and mixed revenue forecasts, hitting a 52-week low. An analyst from Wells Fargo set a price target slightly below the current price, signaling limited growth pot...
Coda Octopus Group reported Q3 earnings per share of $0.12 and revenue of $7.7 million, exceeding analyst expectations. The company's growth was driven by its defense engineering and acoustic businesses, which offset a decline in marine technology sa...
Lennar Corporation is set to report its Q3 earnings on September 16, 2026, with analysts expecting a decline in both earnings per share and revenue compared to last year. The forecasted EPS is $1.29 on revenue of about $8.32 billion, down from $2.00 ...
Baldwin Group is going private in a $7.7 billion all-cash deal led by Sequence Holdings and DFO Management, offering shareholders $32.50 per share, an 88% premium over the June 2026 price. The transaction will delist Baldwin from Nasdaq and is expect...
